NCT07171606View on ClinicalTrials.gov

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2027

Conditions

First-line Advanced NSCLC Patients

Interventions

DRUG

SSGJ-706

PD-1/PD-L1 bispecific antibody

DRUG

pemetrexed /carboplatin

chemotherapy

DRUG

Carboplatin/Paclitaxel

chemotherapy

DRUG

PD-1 Inhibitor + Chemotherapy

control group

Trial Locations (1)

Unknown

Institute of The Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors

lead

Shenyang Sunshine Pharmaceutical Co., LTD.

INDUSTRY

NCT07171606 - A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients | Biotech Hunter | Biotech Hunter